Login / Signup

Identification of an H-Ras nanocluster disrupting peptide.

Candy Laura SteffenGanesh Babu ManoharanKarolina PavicAlejandro Yeste-VázquezMatias KnuuttilaNeha AroraYong ZhouHarri HärmäAnthoula GaigneauxTom N GrossmannDaniel Kwaku Abankwa
Published in: Communications biology (2024)
Hyperactive Ras signalling is found in most cancers. Ras proteins are only active in membrane nanoclusters, which are therefore potential drug targets. We previously showed that the nanocluster scaffold galectin-1 (Gal1) enhances H-Ras nanoclustering via direct interaction with the Ras binding domain (RBD) of Raf. Here, we establish that the B-Raf preference of Gal1 emerges from the divergence of the Raf RBDs at their proposed Gal1-binding interface. We then identify the L5UR peptide, which disrupts this interaction by binding with low micromolar affinity to the B- and C-Raf-RBDs. Its 23-mer core fragment is sufficient to interfere with H-Ras nanoclustering, modulate Ras-signalling and moderately reduce cell viability. These latter two phenotypic effects may also emerge from the ability of L5UR to broadly engage with several RBD- and RA-domain containing Ras interactors. The L5UR-peptide core fragment is a starting point for the development of more specific reagents against Ras-nanoclustering and -interactors.
Keyphrases
  • wild type
  • rheumatoid arthritis
  • mass spectrometry
  • disease activity
  • ankylosing spondylitis
  • idiopathic pulmonary fibrosis
  • capillary electrophoresis